CL2019002662A1 - Inhibidores de ip6k. - Google Patents
Inhibidores de ip6k.Info
- Publication number
- CL2019002662A1 CL2019002662A1 CL2019002662A CL2019002662A CL2019002662A1 CL 2019002662 A1 CL2019002662 A1 CL 2019002662A1 CL 2019002662 A CL2019002662 A CL 2019002662A CL 2019002662 A CL2019002662 A CL 2019002662A CL 2019002662 A1 CL2019002662 A1 CL 2019002662A1
- Authority
- CL
- Chile
- Prior art keywords
- ip6k
- heart failure
- inhibitors
- expected
- useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 abstract 3
- 101100540484 Homo sapiens PPIP5K1 gene Proteins 0.000 abstract 2
- 102100037739 Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 1 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN TIENE POR OBJETO PROPORCIONAR UN COMPUESTO HETEROCÍCLICO QUE TIENE UNA ACCIÓN INHIBIDORA DE IP6K Y SE ESPERA QUE SEA DE UTILIDAD COMO UN AGENTE PREVENTIVO O TERAPÉUTICO PARA ENFERMEDADES TALES COMO INSUFICIENCIA CARDÍACA, DIABETES, Y SIMILARES. UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I): EN DONDE CADA SÍMBOLO ES COMO SE DEFINE EN LA MEMORIA DESCRIPTIVA, O UNA DE SUS SALES TIENE UNA ACCIÓN INHIBIDORA DE IP6K Y SE ESPERA QUE SEA DE UTILIDAD COMO UN AGENTE PREVENTIVO O TERAPÉUTICO PARA ENFERMEDADES TALES COMO INSUFICIENCIA CARDÍACA, DIABETES, Y SIMILARES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017066579 | 2017-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002662A1 true CL2019002662A1 (es) | 2020-01-24 |
Family
ID=62134158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002662A CL2019002662A1 (es) | 2017-03-30 | 2019-09-16 | Inhibidores de ip6k. |
Country Status (24)
Country | Link |
---|---|
US (1) | US10968178B2 (es) |
EP (1) | EP3601256A1 (es) |
JP (1) | JP7063915B2 (es) |
KR (1) | KR102597117B1 (es) |
CN (1) | CN110461828B (es) |
AR (1) | AR111307A1 (es) |
AU (1) | AU2018246053B2 (es) |
BR (1) | BR112019020194A2 (es) |
CA (1) | CA3057821A1 (es) |
CL (1) | CL2019002662A1 (es) |
CO (1) | CO2019012125A2 (es) |
EA (1) | EA038177B1 (es) |
EC (1) | ECSP19077969A (es) |
IL (1) | IL269347B2 (es) |
JO (1) | JOP20180029A1 (es) |
MA (1) | MA49006A (es) |
MX (1) | MX2019011783A (es) |
PE (1) | PE20191656A1 (es) |
PH (1) | PH12019502248A1 (es) |
SG (1) | SG11201908894SA (es) |
TW (1) | TWI778038B (es) |
UA (1) | UA125445C2 (es) |
WO (1) | WO2018182051A1 (es) |
ZA (1) | ZA201907136B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3570844B1 (en) | 2017-01-20 | 2023-09-06 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
MA48994A (fr) | 2017-03-30 | 2020-02-05 | Hoffmann La Roche | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
US11478479B2 (en) | 2018-02-16 | 2022-10-25 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
UY39609A (es) * | 2021-01-12 | 2022-08-31 | Servier Lab | Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos |
WO2023154466A1 (en) * | 2022-02-11 | 2023-08-17 | The University Of North Carolina At Chapel Hill | Arylbenzoisoxazole compounds as ip6k and ipmk inhibitors and methods of use thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4617302A (en) | 1984-10-15 | 1986-10-14 | Eli Lilly And Company | Inotropic agents |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
US7045527B2 (en) * | 2002-09-24 | 2006-05-16 | Amgen Inc. | Piperidine derivatives |
KR20050062645A (ko) | 2002-11-01 | 2005-06-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 신경병증의 예방 또는 치료제 |
CA2505322A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function regulator |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
EP1698624B1 (en) | 2003-12-26 | 2012-06-27 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
CA2605778A1 (en) | 2005-04-20 | 2006-10-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
US8153694B2 (en) | 2005-07-29 | 2012-04-10 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
WO2007013694A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | フェノキシアルカン酸化合物 |
JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
EP2041123B9 (en) | 2006-06-27 | 2013-01-02 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2008047821A1 (fr) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné |
BRPI0717722A2 (pt) | 2006-10-19 | 2013-10-29 | Takeda Pharmaceutical | Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo |
EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
TW200838515A (en) | 2007-02-09 | 2008-10-01 | Takeda Pharmaceutical | Fused ring compound |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
JP2011502958A (ja) | 2007-06-19 | 2011-01-27 | 武田薬品工業株式会社 | グルコキナーゼ活性化インダゾール化合物 |
EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
JP6197282B2 (ja) | 2012-12-03 | 2017-09-20 | 凸版印刷株式会社 | 電極および色素増感太陽電池 |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
MA48994A (fr) | 2017-03-30 | 2020-02-05 | Hoffmann La Roche | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 |
-
2017
- 2017-03-30 JO JOP/2018/0029A patent/JOP20180029A1/ar unknown
-
2018
- 2018-03-28 AR ARP180100763A patent/AR111307A1/es unknown
- 2018-03-29 PE PE2019001965A patent/PE20191656A1/es unknown
- 2018-03-29 EP EP18723386.1A patent/EP3601256A1/en active Pending
- 2018-03-29 MX MX2019011783A patent/MX2019011783A/es unknown
- 2018-03-29 EA EA201992306A patent/EA038177B1/ru unknown
- 2018-03-29 UA UAA201910745A patent/UA125445C2/uk unknown
- 2018-03-29 TW TW107110992A patent/TWI778038B/zh active
- 2018-03-29 SG SG11201908894S patent/SG11201908894SA/en unknown
- 2018-03-29 MA MA049006A patent/MA49006A/fr unknown
- 2018-03-29 WO PCT/JP2018/014502 patent/WO2018182051A1/en unknown
- 2018-03-29 JP JP2019554003A patent/JP7063915B2/ja active Active
- 2018-03-29 AU AU2018246053A patent/AU2018246053B2/en active Active
- 2018-03-29 KR KR1020197031524A patent/KR102597117B1/ko active IP Right Grant
- 2018-03-29 BR BR112019020194A patent/BR112019020194A2/pt unknown
- 2018-03-29 IL IL269347A patent/IL269347B2/en unknown
- 2018-03-29 US US16/496,530 patent/US10968178B2/en active Active
- 2018-03-29 CN CN201880022971.2A patent/CN110461828B/zh active Active
- 2018-03-29 CA CA3057821A patent/CA3057821A1/en active Pending
-
2019
- 2019-09-16 CL CL2019002662A patent/CL2019002662A1/es unknown
- 2019-09-27 PH PH12019502248A patent/PH12019502248A1/en unknown
- 2019-10-29 ZA ZA2019/07136A patent/ZA201907136B/en unknown
- 2019-10-29 CO CONC2019/0012125A patent/CO2019012125A2/es unknown
- 2019-10-30 EC ECSENADI201977969A patent/ECSP19077969A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002662A1 (es) | Inhibidores de ip6k. | |
CL2020000272A1 (es) | Compuesto heterocíclico y su uso. | |
UY35821A (es) | Compuesto heterocíclico | |
ECSP13012719A (es) | Compuesto bicíclico | |
DOP2015000140A (es) | Compuesto heterocíclico | |
DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
CL2016003326A1 (es) | Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t | |
BR112015019627A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
EA201591743A8 (ru) | СТИМУЛЯТОРЫ sGC | |
AR104342A1 (es) | Compuesto heterocíclico | |
BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
CL2017000006A1 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
BR112016028022A2 (pt) | compostos de sulfonamida e seus usos como inibidores de stat5 | |
CO2020003134A2 (es) | Moduladores de la expresión de enac | |
CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
AR107163A1 (es) | Inhibidores de quinasa | |
BR112017008594A2 (pt) | derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia | |
CO2019012270A2 (es) | Compuesto heterocíclico | |
CO2019012295A2 (es) | Compuesto heterocíclico | |
CL2019002203A1 (es) | Nuevos compuestos heterocíclicos y sus usos en la prevención o el tratamiento de infecciones bacterianas. | |
UY36363A (es) | Compuesto heterocíclico fusionado |